Ravit Geva

15.8k total citations · 3 hit papers
134 papers, 5.3k citations indexed

About

Ravit Geva is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ravit Geva has authored 134 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Oncology, 33 papers in Pathology and Forensic Medicine and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ravit Geva's work include Colorectal Cancer Treatments and Studies (45 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Genetic factors in colorectal cancer (31 papers). Ravit Geva is often cited by papers focused on Colorectal Cancer Treatments and Studies (45 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Genetic factors in colorectal cancer (31 papers). Ravit Geva collaborates with scholars based in Israel, United States and South Korea. Ravit Geva's co-authors include Shilpa Gupta, Kumudu Pathiraja, Jonathan D. Cheng, Laura Q.M. Chow, Raanan Berger, Lajos Pusztai, Laurence Buisseret, Vassiliki Karantza, Kei Muro and Talia Golan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ravit Geva

126 papers receiving 5.2k citations

Hit Papers

Pembrolizumab in Patients With Advanced Triple-Negative B... 2016 2026 2019 2022 2016 2016 2018 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
    2016 1.1k citations Ravit Geva et al. Journal of Clinical Oncology profile →
  2. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
    2016 848 citations Kei Muro, Hyun Cheol Chung et al. profile →
  3. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
    2018 329 citations Kei Muro, Ravit Geva et al. British Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ravit Geva Israel 33 4.1k 1.6k 1.2k 880 827 134 5.3k
Wei Qiao United States 40 2.7k 0.7× 1.3k 0.8× 1.3k 1.0× 932 1.1× 1.0k 1.3× 162 5.7k
Simon Pernot France 25 2.2k 0.5× 1.1k 0.7× 938 0.8× 547 0.6× 609 0.7× 99 3.5k
Fadi Braiteh United States 29 4.2k 1.0× 2.0k 1.2× 1.1k 1.0× 695 0.8× 940 1.1× 76 5.6k
Hiroyuki Katoh Japan 34 1.8k 0.4× 1.5k 0.9× 937 0.8× 807 0.9× 633 0.8× 163 4.6k
Zhaode Bu China 26 1.5k 0.4× 1.3k 0.8× 1.3k 1.1× 830 0.9× 611 0.7× 108 3.9k
Satoru Iwasa Japan 30 2.7k 0.7× 1.9k 1.2× 352 0.3× 1.3k 1.4× 315 0.4× 255 4.4k
Filippo Pietrantonio Italy 37 2.9k 0.7× 1.5k 0.9× 227 0.2× 1.1k 1.3× 1.2k 1.5× 298 5.0k
Salah‐Eddin Al‐Batran Germany 39 3.2k 0.8× 3.3k 2.0× 385 0.3× 1.9k 2.1× 532 0.6× 214 5.6k
Scott A. Laurie Canada 36 4.3k 1.0× 3.3k 2.0× 622 0.5× 1.2k 1.4× 685 0.8× 163 6.3k
Geoffrey Y. Ku United States 30 2.2k 0.5× 1.4k 0.9× 944 0.8× 1.0k 1.2× 208 0.3× 170 3.4k

Countries citing papers authored by Ravit Geva

Since Specialization
Citations

This map shows the geographic impact of Ravit Geva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravit Geva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravit Geva more than expected).

Fields of papers citing papers by Ravit Geva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravit Geva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravit Geva. The network helps show where Ravit Geva may publish in the future.

Co-authorship network of co-authors of Ravit Geva

This figure shows the co-authorship network connecting the top 25 collaborators of Ravit Geva. A scholar is included among the top collaborators of Ravit Geva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravit Geva. Ravit Geva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Armstrong, Andrew J., Ravit Geva, Hyun Cheol Chung, et al.. (2024). CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Investigational New Drugs. 42(1). 145–159. 33 indexed citations
2.
Hubert, Ayala, Sofia Man, Ravit Geva, et al.. (2024). Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data. ESMO Open. 9(8). 103648–103648. 1 indexed citations
3.
Gutfeld, Orit, Tatiana Rabin, Leor Zach, et al.. (2024). The effect of long-standing lymphopenia after radiation therapy on survival in rectal cancer. Surgical Oncology. 56. 102119–102119. 1 indexed citations
4.
Klausner, Joseph M., Yona Greenman, Naftali Stern, et al.. (2023). A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors. Biomedicines. 11(2). 407–407. 3 indexed citations
5.
6.
Tabernero, Josep, Eric Van Cutsem, Elena Garralda, et al.. (2023). A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAFV600E-MutantKRASWild-Type Metastatic Colorectal Cancer. The Oncologist. 28(3). 230–238. 34 indexed citations
7.
Brenner, Baruch, Ayala Hubert, Sofia Man, et al.. (2023). Treatments and clinical outcomes in stage II colon cancer (CC) patients (pts) with 12-gene Oncotype DX Colon Recurrence Score assay-guided therapy: Real-world data.. Journal of Clinical Oncology. 41(16_suppl). 3620–3620.
8.
Keizman, Daniel, Moshe Frenkel, Avivit Peer, et al.. (2023). Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study. Nutrients. 15(16). 3533–3533. 6 indexed citations
9.
Le, Dung T., Luis A. Díaz, Tae Won Kim, et al.. (2023). Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164. European Journal of Cancer. 186. 185–195. 46 indexed citations
10.
Garralda, Elena, Ravit Geva, Eytan Ben‐Ami, et al.. (2020). 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A250.2–A251. 6 indexed citations
11.
12.
Golan, Talia, Guy Lahat, Ido Nachmany, et al.. (2020). Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. Annals of Surgical Oncology. 27(10). 3963–3970. 51 indexed citations
13.
14.
Shroff, Rachna T., Andrew Hendifar, Robert R. McWilliams, et al.. (2018). Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precision Oncology. 2018(2). 1–15. 137 indexed citations
15.
Geva, Ravit, Juanita Lopez, Sarah Danson, et al.. (2018). Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. European Journal of Nuclear Medicine and Molecular Imaging. 46(5). 1092–1101. 15 indexed citations
16.
Díaz, Luis A., Aurélien Marabelle, T.W. Kim, et al.. (2017). Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Annals of Oncology. 28. v128–v129. 52 indexed citations
17.
Wainberg, Zev A., Shadia I. Jalal, Kei Muro, et al.. (2017). KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer. Annals of Oncology. 28. v616–v617. 30 indexed citations
18.
Fidder, Herma H., Arié Figer, Ravit Geva, et al.. (2005). Genetic Analyses in Consecutive Israeli Jewish Colorectal Cancer Patients. The American Journal of Gastroenterology. 100(6). 1376–1380. 15 indexed citations
19.
Figer, Arié, Anna Kaplan, Ravit Geva, et al.. (2002). Mutational Analysis of the hMSH6 Gene in Familial and Early-Onset Colorectal and Endometrial Cancer in Israeli Patients. Genetic Testing. 6(4). 323–326. 1 indexed citations
20.
Figer, Arié, et al.. (2001). Genetic analysis of the APC gene regions involved in attenuated APC phenotype in Israeli patients with early onset and familial colorectal cancer. British Journal of Cancer. 85(4). 523–526. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wei Qiao Breakdown of academic impact, for papers by Simon Pernot Breakdown of academic impact, for papers by Fadi Braiteh Breakdown of academic impact, for papers by Hiroyuki Katoh Breakdown of academic impact, for papers by Zhaode Bu Breakdown of academic impact, for papers by Satoru Iwasa Breakdown of academic impact, for papers by Filippo Pietrantonio Breakdown of academic impact, for papers by Salah‐Eddin Al‐Batran Breakdown of academic impact, for papers by Scott A. Laurie Breakdown of academic impact, for papers by Geoffrey Y. Ku
Rankless by CCL
2026